Unknown

Dataset Information

0

Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.


ABSTRACT: BACKGROUND:Reducing doses of antiretroviral drugs, including stavudine (d4T), may lower toxicity, while preserving efficacy. There are substantial concerns about renal and bone toxicities of tenofovir disoproxil fumarate (TDF). SETTING:HIV-1-infected treatment-naive adults in India, South Africa, and Uganda. METHODS:A phase-4, 96-week, randomized, double-blind, noninferiority trial compared d4T 20 mg twice daily and TDF, taken in combination with lamivudine (3TC) and efavirenz (EFV). The primary endpoint was the proportion of participants with HIV-1 RNA <50 copies per milliliter at 48 weeks. Adverse events assessments included measures of bone density and body fat. The trial is registered on Clinicaltrials.gov (NCT02670772). RESULTS:Between 2012 and 2014, 536 participants were recruited per arm. At week 96, trial completion rates were 75.7% with d4T/3TC/EFV (n = 406) and 82.1% with TDF/3TC/EFV (n = 440, P = 0.011). Noncompletion was largely due to virological failure [6.2% (33) with d4T/3TC/EFV versus 5.4% (29) with TDF/3TC/EFV; P = 0.60]. For the primary endpoint, d4T/3TC/EFV was noninferior to TDF/3TC/EFV (79.3%, 425/536 versus 80.8% 433/536; difference = -1.49%, 95% CI: -6.3 to 3.3; P < 0.001). Drug-related adverse event discontinuations were higher with d4T (6.7%, 36), than TDF (1.1%, 6; P < 0.001). Lipodystrophy was more common with d4T (5.6%, 30) than TDF (0.2%, 1; P < 0.001). Creatinine clearance increased in both arms, by 18.1 mL/min in the d4T arm and 14.2 mL/min with TDF (P = 0.03). Hip bone density measures, however, showed greater loss with TDF. CONCLUSIONS:Low-dose d4T combined with 3TC/EFV demonstrated noninferior virological efficacy compared with TDF/3TC/EFV, but mitochondrial toxicity remained high. Little renal toxicity occurred in either arm. Implications of bone mineral density changes with TDF warrant investigation.

SUBMITTER: Venter WDF 

PROVIDER: S-EPMC6358196 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.

Venter Willem Daniel Francois WDF   Kambugu Andrew A   Chersich Matthew F MF   Becker Stephen S   Hill Andrew A   Arulappan Natasha N   Moorhouse Michelle M   Majam Mohammed M   Akpomiemie Godspower G   Sokhela Simiso S   Poongulali Selvamuthu S   Feldman Charles C   Duncombe Chris C   Ripin David H Brown DHB   Vos Alinda A   Kumarasamy Nagalingeswaran N  

Journal of acquired immune deficiency syndromes (1999) 20190201 2


<h4>Background</h4>Reducing doses of antiretroviral drugs, including stavudine (d4T), may lower toxicity, while preserving efficacy. There are substantial concerns about renal and bone toxicities of tenofovir disoproxil fumarate (TDF).<h4>Setting</h4>HIV-1-infected treatment-naive adults in India, South Africa, and Uganda.<h4>Methods</h4>A phase-4, 96-week, randomized, double-blind, noninferiority trial compared d4T 20 mg twice daily and TDF, taken in combination with lamivudine (3TC) and efavir  ...[more]

Similar Datasets

| S-EPMC6295103 | biostudies-literature
| S-EPMC8118264 | biostudies-literature
| S-EPMC8223849 | biostudies-literature
| S-EPMC8420957 | biostudies-literature
| S-EPMC7241516 | biostudies-literature
| S-EPMC8020360 | biostudies-literature
| S-EPMC3855348 | biostudies-literature
| S-EPMC9292801 | biostudies-literature
| S-EPMC4499796 | biostudies-literature
| S-EPMC5427981 | biostudies-literature